Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-439-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees47
Next Earnings Date2/28/2019 (Estimated)
OptionableNot Optionable
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions
What is Kiniksa Pharmaceuticals' stock symbol?
Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."
How were Kiniksa Pharmaceuticals' earnings last quarter?
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) released its earnings results on Thursday, November, 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.
When is Kiniksa Pharmaceuticals' next earnings date?
What price target have analysts set for KNSA?
4 analysts have issued 1-year price targets for Kiniksa Pharmaceuticals' stock. Their forecasts range from $29.00 to $44.00. On average, they anticipate Kiniksa Pharmaceuticals' share price to reach $35.3333 in the next year. This suggests a possible upside of 100.5% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.
What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.
Has Kiniksa Pharmaceuticals been receiving favorable news coverage?
Headlines about KNSA stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Kiniksa Pharmaceuticals' key competitors?
Some companies that are related to Kiniksa Pharmaceuticals include Horizon Pharma (HZNP), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of Kiniksa Pharmaceuticals own?
Who are Kiniksa Pharmaceuticals' key executives?
Kiniksa Pharmaceuticals' management team includes the folowing people:
- Mr. Sanj K. Patel, CEO & Chairman (Age 49)
- Mr. Stephen Mahoney, Pres & COO (Age 48)
- Dr. John F. Paolini, Chief Medical Officer (Age 54)
- Mr. Chris Heberlig, Chief Financial Officer (Age 44)
- Mark Ragosa, VP of Investor Relations
When did Kiniksa Pharmaceuticals IPO?
(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Kiniksa Pharmaceuticals' major shareholders?
Kiniksa Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Hillhouse Capital Advisors Ltd. (2.57%), BlackRock Inc. (1.30%), Millennium Management LLC (0.20%), Victory Capital Management Inc. (0.17%), Foresite Capital Management IV LLC (0.12%) and Alps Advisors Inc. (0.07%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Institutional Ownership Trends for Kiniksa Pharmaceuticals.
Which major investors are selling Kiniksa Pharmaceuticals stock?
Which major investors are buying Kiniksa Pharmaceuticals stock?
KNSA stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., BlackRock Inc., Virtus ETF Advisers LLC, Algert Global LLC, Bank of America Corp DE, D. E. Shaw & Co. Inc., Alps Advisors Inc. and Rhumbline Advisers. Company insiders that have bought Kiniksa Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Insider Buying and Selling for Kiniksa Pharmaceuticals.
How do I buy shares of Kiniksa Pharmaceuticals?
Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kiniksa Pharmaceuticals' stock price today?
One share of KNSA stock can currently be purchased for approximately $17.62.
How big of a company is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals has a market capitalization of $953.95 million. Kiniksa Pharmaceuticals employs 47 workers across the globe.
What is Kiniksa Pharmaceuticals' official website?
How can I contact Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]
MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
